Updated Survival, Quality of Life (QOL), and Safety Data of Radium-223 Chloride (RA-223) in Patients with Castration-Resistant Prostate Cancer (CRPC) with Bone Metastases from the Phase 3 Double-Blind, Randomized, Multinational Study (ALSYMPCA)

Phase 3 ◽

Double Blind ◽

Castration Resistant ◽

714 PAIN AND QUALITY OF LIFE (QOL) ANALYSES FROM THE PHASE 3 RANDOMIZED ALSYMPCA STUDY WITH RADIUM-223 DICHLORIDE (RA-223) IN CASTRATION-RESISTANT PROSTATE CANCER (CRPC) PATIENTS WITH BONE METASTASES

10.1016/j.juro.2013.02.273 ◽

2013 ◽

Vol 189 (4S) ◽

Cited By ~ 5

Author(s):

Michael Tomblyn ◽

Sten Nilsson ◽

Nicholas Vogelzang ◽

A. Oliver Sartor ◽

Paul Cislo ◽

...

Keyword(s):

Quality Of Life ◽

Prostate Cancer ◽

Bone Metastases ◽

Phase 3 ◽

Castration Resistant ◽

715 CABAZITAXEL FOR METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC): FINAL QUALITY OF LIFE (QOL) RESULTS WITH SAFETY DATA FROM THE UNITED KINGDOM (UK) EARLY ACCESS PROGRAMME (EAP) (NCT01254279)

10.1016/j.juro.2013.02.274 ◽

2013 ◽

Vol 189 (4S) ◽

Cited By ~ 1

Author(s):

Amit Bahl ◽

Susan Masson ◽

Zafar Malik ◽

Alison Birtle ◽

Santhanam Sundar ◽

...

Keyword(s):

Quality Of Life ◽

Prostate Cancer ◽

United Kingdom ◽

Safety Data ◽

Early Access ◽

The United Kingdom ◽

Castration Resistant ◽

Access Programme

Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(18)30456-x ◽

2018 ◽

Vol 19 (10) ◽

pp. 1404-1416 ◽

Cited By ~ 44

Author(s):

Fred Saad ◽

David Cella ◽

Ethan Basch ◽

Boris A Hadaschik ◽

Paul N Mainwaring ◽

...

Keyword(s):

Quality Of Life ◽

Prostate Cancer ◽

Health Related Quality ◽

Phase 3 ◽

Castration Resistant ◽

Related Quality ◽

Health Related

Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial

The Lancet Oncology ◽

10.1016/s1470-2045(14)70474-7 ◽

2014 ◽

Vol 15 (12) ◽

pp. 1397-1406 ◽

Cited By ~ 208

Author(s):

Peter Hoskin ◽

Oliver Sartor ◽

Joe M O'Sullivan ◽

Dag Clement Johannessen ◽

Svein I Helle ◽

...

Keyword(s):

Prostate Cancer ◽

Bone Metastases ◽

Subgroup Analysis ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Castration Resistant ◽

Re: Effect of Radium-223 Dichloride on Symptomatic Skeletal Events in Patients with Castration-Resistant Prostate Cancer and Bone Metastases: Results from a Phase 3, Double-Blind, Randomised Trial

10.1016/j.juro.2014.12.077 ◽

2015 ◽

Vol 193 (3) ◽

pp. 847-848

Author(s):

Samir S. Taneja

Keyword(s):

Prostate Cancer ◽

Bone Metastases ◽

Randomised Trial ◽

Phase 3 ◽

Double Blind ◽

Castration Resistant ◽

Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial

The Lancet Oncology ◽

10.1016/s1470-2045(14)70303-1 ◽

2014 ◽

Vol 15 (10) ◽

pp. 1147-1156 ◽

Cited By ~ 122

Author(s):

Karim Fizazi ◽

Howard I Scher ◽

Kurt Miller ◽

Ethan Basch ◽

Cora N Sternberg ◽

...

Keyword(s):

Quality Of Life ◽

Prostate Cancer ◽

Related Event ◽

Phase 3 ◽

Castration Resistant ◽

Skeletal Related Event

Re: Effect of Enzalutamide on Time to First Skeletal-Related Event, Pain, and Quality of Life in Men with Castration-Resistant Prostate Cancer: Results from the Randomised, Phase 3 AFFIRM Trial

10.1016/j.juro.2015.05.065 ◽

2015 ◽

Vol 194 (2) ◽

pp. 392-393

Author(s):

Samir S. Taneja

Keyword(s):

Quality Of Life ◽

Prostate Cancer ◽

Related Event ◽

Phase 3 ◽

Castration Resistant ◽

Skeletal Related Event

Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(18)30860-x ◽

2019 ◽

Vol 20 (3) ◽

pp. 408-419 ◽

Cited By ~ 89

Author(s):

Matthew Smith ◽

Chris Parker ◽

Fred Saad ◽

Kurt Miller ◽

Bertrand Tombal ◽

...

Keyword(s):

Prostate Cancer ◽

Bone Metastases ◽

Abiraterone Acetate ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Castration Resistant ◽

Optimising Radium 223 Therapy for Metastatic Castration-Resistant Prostate Cancer –5-year Real-World Outcome: Focusing on Treatment Sequence and Quality of Life

Clinical Oncology ◽

10.1016/j.clon.2020.05.002 ◽

2020 ◽

Vol 32 (10) ◽

pp. e177-e187 ◽

Cited By ~ 1

Author(s):

X.Y. Jiang ◽

S. Atkinson ◽

R. Pearson ◽

D. Leaning ◽

S. Cumming ◽

...

Keyword(s):

Quality Of Life ◽

Prostate Cancer ◽

Real World ◽

Treatment Sequence ◽

Castration Resistant ◽

Pain and quality of life in metastasized Castration Resistant Prostate Cancer patients treated with Radium-223 (ROTOR registry): A prospective observational registry in a non-study population

Annals of Oncology ◽

10.1093/annonc/mdy284.038 ◽

2018 ◽

Vol 29 ◽

pp. viii290

Author(s):

R. Louhanepessy ◽

S. Badrising ◽

V. Vd Noort ◽

J.L. Coenen ◽

A. Oostdijk ◽

...

Keyword(s):

Quality Of Life ◽

Prostate Cancer ◽

Cancer Patients ◽

Castration Resistant ◽

Radium 223 ◽

Study Population